ResMed Unveils 2030 Strategy to Drive Growth, Profitability, and Shareholder Returns
ResMed (NYSE: RMD, ASX: RMD) unveiled its 2030 Strategy at an Investor Day in New York City, aiming to drive growth, profitability, and shareholder returns. The company's ambition is to help over 500 million people achieve their full health potential by 2030. ResMed introduced an updated five-year financial outlook, expecting high-single-digit revenue growth and earnings growth higher than revenue growth.
The 2030 Strategy focuses on three pillars: growing the core sleep apnea franchise, capitalizing on opportunities in broader sleep and breathing health, and investing 7% of revenue into R&D to create an integrated digital ecosystem for home health technology. ResMed plans to leverage its leadership in connected digital health, transforming sleep health, breathing health, and health tech at home through innovative products and digital solutions.
ResMed (NYSE: RMD, ASX: RMD) ha presentato la sua Strategia 2030 durante un Investor Day a New York, con l'obiettivo di promuovere crescita, redditività e ritorni per gli azionisti. L'ambizione dell'azienda è quella di aiutare oltre 500 milioni di persone a raggiungere il loro pieno potenziale di salute entro il 2030. ResMed ha introdotto una prospettiva finanziaria aggiornata di cinque anni, prevedendo una crescita dei ricavi a una cifra alta e una crescita degli utili superiore a quella dei ricavi.
La Strategia 2030 si concentra su tre pilastri: crescita del franchising principale per l'apnea notturna, sfruttamento delle opportunità nel più ampio settore della salute del sonno e della respirazione, e investimento del 7% dei ricavi in R&D per creare un ecosistema digitale integrato per la tecnologia sanitaria domestica. ResMed mira a sfruttare la sua leadership nella salute digitale connessa, trasformando la salute del sonno, la salute respiratoria e la tecnologia sanitaria a casa attraverso prodotti innovativi e soluzioni digitali.
ResMed (NYSE: RMD, ASX: RMD) presentó su Estrategia 2030 en un Investor Day en Nueva York, con el objetivo de impulsar el crecimiento, la rentabilidad y los retornos para los accionistas. La ambición de la empresa es ayudar a más de 500 millones de personas a alcanzar su máximo potencial de salud para 2030. ResMed introdujo una perspectiva financiera actualizada a cinco años, esperando un crecimiento de ingresos de un solo dígito alto y un crecimiento de ganancias que supere al de ingresos.
La Estrategia 2030 se centra en tres pilares: hacer crecer la franquicia principal de apnea del sueño, aprovechar las oportunidades en el ámbito más amplio de la salud del sueño y la respiración, e invertir el 7% de los ingresos en I+D para crear un ecosistema digital integrado para la tecnología de salud en el hogar. ResMed planea aprovechar su liderazgo en salud digital conectada, transformando la salud del sueño, la salud respiratoria y la tecnología de salud en el hogar a través de productos innovadores y soluciones digitales.
ResMed (NYSE: RMD, ASX: RMD)는 뉴욕에서 열린 투자자 날 행사에서 2030 전략을 발표하며 성장, 수익성 및 주주 수익을 촉진할 목표를 세웠습니다. 이 회사의 야망은 5억 명 이상의 사람들이 2030년까지 건강 잠재력을 최대한 발휘할 수 있도록 돕는 것입니다. ResMed는 5년 재무 전망을 업데이트하고, 고수익 성장과 더불어 수익 성장률보다 높은 이익 성장을 예상했습니다.
2030 전략은 세 가지 기둥에 초점을 맞추고 있습니다: 주요 수면 무호흡증 프랜차이즈의 성장, 더 넓은 수면 및 호흡 건강의 기회를 활용하고, 수익의 7%를 R&D에 투자하여 홈 헬스 기술을 위한 통합 디지털 생태계를 만드는 것입니다. ResMed는 연결된 디지털 건강에서의 선두 지위를 활용하여 혁신적인 제품과 디지털 솔루션을 통해 수면 건강, 호흡 건강, 가정 내 건강 기술을 변화시킬 계획입니다.
ResMed (NYSE: RMD, ASX: RMD) a dévoilé sa Stratégie 2030 lors d'une Journée des Investisseurs à New York, visant à stimuler la croissance, la rentabilité et les rendements pour les actionnaires. L'ambition de l'entreprise est d'aider plus de 500 millions de personnes à atteindre leur plein potentiel de santé d'ici 2030. ResMed a introduit une perspective financière mise à jour sur cinq ans, prévoyant une croissance à un chiffre élevé des revenus et une croissance des bénéfices supérieure à celle des revenus.
La Stratégie 2030 se concentre sur trois piliers : développer le secteur principal de l'apnée du sommeil, saisir les opportunités dans le domaine plus large de la santé du sommeil et de la respiration, et investir 7 % des revenus en R&D pour créer un écosystème numérique intégré pour la technologie de santé à domicile. ResMed prévoit de tirer parti de son leadership dans la santé numérique connectée, transformant la santé du sommeil, la santé respiratoire et la technologie de la santé à domicile grâce à des produits innovants et des solutions numériques.
ResMed (NYSE: RMD, ASX: RMD) stellte bei einem Investor Day in New York seine 2030-Strategie vor, die darauf abzielt, Wachstum, Rentabilität und Renditen für die Aktionäre zu fördern. Das Ziel des Unternehmens ist es, mehr als 500 Millionen Menschen bis 2030 zu helfen, ihr volles Gesundheitspotenzial zu erreichen. ResMed führte eine aktualisierte Finanzprognose für fünf Jahre ein und erwartet ein Wachstum der Einnahmen im hohen einstelligen Bereich sowie ein höheres Wachstum der Gewinne im Vergleich zum Wachstum der Einnahmen.
Die 2030-Strategie konzentriert sich auf drei Säulen: das Wachstum des Hauptgeschäfts mit Schlafapnoe, die Nutzung von Chancen im Bereich Schlaf- und Atemgesundheit und die Investition von 7 % des Umsatzes in Forschung und Entwicklung, um ein integriertes digitales Ökosystem für die Heimgesundheitstechnologie zu schaffen. ResMed plant, seine Führungsposition im Connected Digital Health zu nutzen, um die Schlafgesundheit, die Atemgesundheit und die Gesundheitstechnologie zu Hause durch innovative Produkte und digitale Lösungen zu transformieren.
- Ambitious goal to help over 500 million people achieve full health potential by 2030
- High-single-digit revenue growth expected in five-year outlook
- Earnings growth projected to exceed revenue growth
- 7% of revenue to be invested in R&D for digital ecosystem development
- Strong market position with 28 million patients in AirView platform and 8.3 million in myAir platform
- None.
Insights
ResMed's 2030 Strategy unveiling is a significant development for investors. The company's ambition to help 500 million people by 2030 demonstrates aggressive growth plans. The high-single-digit revenue growth and earnings growth exceeding revenue growth in the five-year outlook are positive indicators.
Key points for investors:
- Focus on core sleep apnea market with new product innovations
- Expansion into adjacent markets like insomnia and COPD
- 7% of revenue invested in R&D
- Leveraging data from 28 million patients in AirView™ platform
- Emphasis on digital health technologies and cloud-connected devices
The strategy aligns with healthcare trends towards home-based care and digital solutions. ResMed's strong market position and focus on innovation could drive long-term growth. However, investors should monitor execution risks and competitive pressures in this rapidly evolving sector.
ResMed's 2030 Strategy presents significant implications for the sleep and respiratory care market. The company's focus on AI/ML-driven technology improvements in CPAP devices and masks could lead to better patient outcomes and adherence rates. The expansion into broader sleep health, particularly addressing the 860 million people with insomnia, represents a substantial market opportunity.
The integration of intelligent products within ResMed's ecosystem aligns with the trend towards personalized medicine. The emphasis on data collection and analysis through platforms like AirView™ and myAir™ could provide valuable insights for both clinical research and product development.
However, the success of this strategy will depend on ResMed's ability to navigate regulatory challenges, ensure data privacy and demonstrate clinical efficacy of new technologies. The company's commitment to R&D investment is promising, but translating innovation into market-leading products will be important for maintaining its competitive edge.
- 2030 ambition to help more than 500 million people worldwide achieve their full health potential
- Showcases integration of intelligent products and solutions within the ResMed ecosystem, designed to deliver a better experience, lower costs, and enhanced outcomes for patients and providers
- Introduces updated five-year financial outlook
NEW YORK and SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today unveiled its 2030 Strategy to drive growth, profitability, and shareholder returns at an Investor Day in New York City. ResMed also announced its five-year revenue and earnings growth outlook, reflecting ResMed’s plans to accelerate product and technology innovation, operational excellence, commercial execution, and financial strength. Driven by the new strategy, ResMed expects to help more than 500 million people worldwide achieve their full health potential in 2030.
“At ResMed, we are celebrating 35 years of growth and innovation with continued evolution, cutting-edge new products, and an unwavering commitment to consumers, providers, and shareholders,” said Mick Farrell, Chairman & CEO of ResMed. “Today, more than 2.3 billion people suffer from major sleep health and breathing issues, the vast majority of which are undiagnosed. By building on our leadership in connected digital health, our 2030 Strategy will further enable us to transform sleep health, breathing health, and health tech at home through world-class products and digital solutions.”
Farrell continued, “We remain focused on delivering a more integrated and intelligent ResMed ecosystem, transforming the consumer and provider experience to offer better care, simplify the health journey, and improve access to our therapies. As we grow our core sleep apnea market, we will also leverage our strong financial position and expertise in broader sleep health to expand into adjacent markets and accelerate the release of new products at an unprecedented velocity.”
New Five-Year Financial Outlook
ResMed’s new five-year financial outlook includes:
- High-single-digit revenue growth
- Earnings growth higher than revenue growth
“Since our last Investor Day in 2021, we have delivered on our commitments, and this new outlook reinforces that ResMed is well positioned to maintain its track record of strong financial performance,” said Brett Sandercock, Chief Financial Officer of ResMed. “Our financial strength and low capital requirements create robust cash generation, and our capital allocation strategy will continue to prioritize innovation – through reinvestment in our core business, a disciplined and strategic approach to M&A, and a balanced capital return policy. We are confident this approach will deliver significant value to shareholders as we execute our 2030 Strategy.”
2030 Strategy
ResMed will achieve its new financial goals through the execution of its clear and focused 2030 Strategy across three pillars to drive growth:
- Grow and differentiate ResMed’s unmatched core sleep apnea franchise, led by demand generation and demand capture: The 2030 Strategy is underpinned by a focus on ResMed’s sleep apnea core, where ResMed is the leader in making smaller, quieter, more comfortable and more connected products that people love – all working together in a more intelligent ecosystem. ResMed will continue differentiating its technology with AI/ML to drive enhanced therapy performance, consumer appeal, and user experience. New commercial excellence and demand generation initiatives will drive more patients into ResMed’s funnel, where they will be served by a robust roadmap of new products, such as the AirTouch N30i next-generation CPAP mask unveiled earlier today.
- Capitalize on ResMed’s market opportunity and brand advantage in broader sleep health and breathing health adjacencies: ResMed’s evolution is designed to capitalize on key macro trends, including the enhanced spotlight on sleep apnea due to pharmaceuticals and consumer tech. Additionally, ResMed’s strong brand and expertise in sleep health position the Company to address the large, untapped sleep health market opportunity, including 860 million people who suffer from insomnia and 480 million people who suffer from COPD.
- Invest
7% of revenue into R&D to invent, create, and differentiate a fully integrated digital ecosystem for health technology delivered at home: With a large installed base of more than 28 million patients in its AirView™ platform – and more than 8.3 million patients registered to the myAir™ platform – ResMed seamlessly integrates devices and data to enhance provider efficiency and enable more personalized care. As ResMed’s 2030 Strategy initiatives drive more patients to its funnel, the ecosystem will further build its data advantage. ResMed’s leading residential care software solutions are a key enabler of its core sleep and breathing health business. They drive substantial revenue synergies, contribute to core demand generation, and provide cohesion and interoperability for ResMed’s AI-driven digital platform.
Implemented in 2023, ResMed’s 2030 Operating Model reorganized the company to ensure it remains product-led, customer-centric, and brand-enhanced. The 2030 Operating Model further accelerates ResMed’s ability to reach consumers where they are, achieve the five-year financial outlook, and unlock value.
2024 Investor Day Webcast and Presentation
The Investor Day webcast replay and presentation slides can be accessed on ResMed’s Investor Relations website at investor.resmed.com.
About ResMed
At ResMed (NYSE: RMD, ASX: RMD), we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 140 countries. To learn more, visit ResMed.com and follow @ResMed.
Safe Harbor Statement
Statements contained in this release that are not historical facts are “forward-looking” statements as contemplated by the Private Securities Litigation Reform Act of 1995. These forward-looking statements – including statements regarding ResMed’s projections of future revenue or earnings, expenses, new product development, new product launches, new markets for its products, the integration of acquisitions, our supply chain, domestic and international regulatory developments, litigation, tax outlook, and the expected impact of macroeconomic conditions of our business – are subject to risks and uncertainties, which could cause actual results to materially differ from those projected or implied in the forward-looking statements. Additional risks and uncertainties are discussed in ResMed’s periodic reports on file with the U.S. Securities & Exchange Commission. ResMed does not undertake to update its forward-looking statements.
| For investors | For media |
| +1 858.836.5000 | +1 619.510.1281 |
| investorrelations@resmed.com | news@resmed.com |
FAQ
What is ResMed's (RMD) 2030 Strategy goal for helping people?
What is ResMed's (RMD) five-year revenue growth outlook?
How much does ResMed (RMD) plan to invest in R&D as part of its 2030 Strategy?
What are the three pillars of ResMed's (RMD) 2030 Strategy?
